Compare DUO & PTHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DUO | PTHL |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.8M |
| IPO Year | 2019 | 2024 |
| Metric | DUO | PTHL |
|---|---|---|
| Price | $1.66 | $0.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 112.0K | 92.2K |
| Earning Date | 03-13-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,189,313.00 | $305,215.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.30 | N/A |
| 52 Week Low | $1.24 | $0.43 |
| 52 Week High | $11.84 | $32.00 |
| Indicator | DUO | PTHL |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 29.40 |
| Support Level | $1.65 | $0.43 |
| Resistance Level | $1.77 | $0.55 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 7.14 | 9.79 |
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.